Clinuvel Pharmaceuticals 配当と自社株買い

配当金基準チェック /06

Clinuvel Pharmaceuticals配当を支払う会社であり、現在の利回りは0.37%です。

主要情報

0.4%

配当利回り

0.1%

バイバック利回り

総株主利回り	0.5%
将来の配当利回り	0.9%
配当成長	24.1%
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	AU$0.050
配当性向	7%

最近の配当と自社株買いの更新

Recent updates

決済の安定と成長

配当データの取得

安定した配当: CUVはAustralian市場で注目すべき配当金を支払っていないため、支払いが安定しているかどうかを確認する必要はありません。

増加する配当: CUVはAustralian市場で注目すべき配当金を支払っていないため、支払額が増加しているかどうかを確認する必要はありません。

配当利回り対市場

Clinuvel Pharmaceuticals 配当利回り対市場

CUV 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (CUV)	0.4%
市場下位25% (AU)	2.6%
市場トップ25% (AU)	6.0%
業界平均 (Biotechs)	2.3%
アナリスト予想 (CUV) (最長3年)	0.9%

注目すべき配当: CUVの配当金 ( 0.37% ) はAustralian市場の配当金支払者の下位 25% ( 2.59% ) と比べると目立ったものではありません。

高配当: CUVの配当金 ( 0.37% ) はAustralian市場の配当金支払者の上位 25% ( 5.95% ) と比較すると低いです。

株主への利益配当

収益カバレッジ: CUV Australian市場において目立った配当金を支払っていません。

株主配当金

キャッシュフローカバレッジ: CUV Australian市場において目立った配当金を支払っていません。

Clinuvel Pharmaceuticals 配当と自社株買い

配当金 基準チェック /06

主要情報

最近の配当と自社株買いの更新

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2023, Payable on September 20, 2023

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2022, Payable on September 21, 2022

Recent updates

CLINUVEL Files Canadian New Drug Submission for SCENESSE® in EPP

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 16, 2024

Dividend of AU$0.05 announced

Full year 2024 earnings released: EPS: AU$0.71 (vs AU$0.62 in FY 2023)

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

Clinuvel Pharmaceuticals Limited Announces Change of Company Secretary

CLINUVEL Announces A Novel Clinical Program

Investor sentiment deteriorates as stock falls 17%

First half 2024 earnings released: EPS: AU$0.22 (vs AU$0.23 in 1H 2023)

Clinuvel Pharmaceuticals Limited to Report First Half, 2024 Results on Feb 22, 2024

Clinuvel Pharmaceuticals Limited Announces Board Changes

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 31, 2023

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2023, Payable on September 20, 2023

Full year 2023 earnings released: EPS: AU$0.62 (vs AU$0.42 in FY 2022)

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Aug 29, 2023

Investor sentiment deteriorates as stock falls 19%

Now 22% undervalued

Clinuvel Pharmaceuticals Ltd Announces the Completion of Manufacture of the First cGMP Batch of PRÉNUMBRA® Instant

Clinuvel Pharmaceuticals Limited Announces First Positive Results from Study Evaluating the Protective Effects of Afamelanotide on Skin Exposed to Ultraviolet Radiation

Clinuvel Pharmaceuticals Limited Announces Neuracthel Manufacturing Processes Advance

Clinuvel Pharmaceuticals Limited Shares the First Results of Phase II Study Evaluating Afamelanotide in Patients with Xeroderma Pigmentosum

No independent directors

Clinuvel Pharmaceuticals Limited Announces Enrollment of First Patient in New Clinical Study CUV104

Investor sentiment improved over the past week

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 26, 2022

Full year 2022 earnings released: EPS: AU$0.42 (vs AU$0.50 in FY 2021)

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2022, Payable on September 21, 2022

Investor sentiment improved over the past week

CLINUVEL PHARMACEUTICALS LIMITED Intends to Evaluate its Drug Candidate PRÉNUMBRA Instant (Afamelanotide) as A Treatment for Patients Diagnosed with Arterial Ischaemic Stroke (AIS) in its Next Clinical Trial (CUV803)

Investor sentiment improved over the past week

Non-Executive Director recently sold AU$356k worth of stock

CLINUVEL Progresses CUV104 Vitiligo Study

CLINUVEL Releases Positive Final Results of the Open Label Pilot Study (CUV801) in Arterial Ischemic Stroke

No independent directors

Clinuvel Pharmaceuticals Ltd Appoints Andrew Likierman as New Non-Executive Director

Clinuvel Pharmaceuticals Limited Announces First XP-V Patient Treated in Third CUV DNA Repair Study

CEO, MD & Director recently sold AU$1.1m worth of stock

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

Now 28% undervalued after recent price drop

Clinuvel Pharmaceuticals Limited Completes Enrolment in CUV801 Stroke Study

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS AU$0.50 (vs AU$0.31 in FY 2020)

CEO, MD & Director recently sold AU$3.7m worth of stock

Non-Executive Director recently sold AU$692k worth of stock

Clinuvel Pharmaceuticals Limited Announces First Stroke Patient Treated with Afamelanotide

CEO, MD & Director recently sold AU$3.1m worth of stock

CEO, MD & Director recently sold AU$2.6m worth of stock

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2021 Results on Aug 31, 2021

Investor sentiment improved over the past week

Revenue misses expectations

First half 2021 earnings released: EPS AU$0.13 (vs AU$0.013 in 1H 2020)

New 90-day low: AU$20.11

Clinuvel Pharmaceuticals Limited to Report First Half, 2021 Results on Feb 26, 2021

Clinuvel Pharmaceuticals Limited Announces First Patient Dosed in SCENESSE DNA Repair Program

New 90-day low - AU$21.04

Earnings released

決済の安定と成長

配当利回り対市場

株主への利益配当

株主配当金

高配当企業の発掘

配当金基準チェック /06